Brain delivery research in public-private partnerships: The IMI-JU COMPACT consortium as an example.
The Blood-Brain Barrier (BBB) represents a major hurdle in the development of treatments for CNS disorders due to the fact that it very effectively keeps drugs, especially biological macromolecules, out of the brain. Concomitantly with the increasing importance of biologics research on the BBB and, more specifically, on brain delivery technologies has intensified in recent years. Public-Private Partnerships (PPPs) represent an innovative opportunity to address such complex challenges as they bring together the best expertise from both industry and academia. Here we present the IMI-JU COMPACT (Collaboration on the Optimisation of Macromolecular Pharmaceutical Access to Cellular Targets) consortium working on nanocarriers for targeted delivery of macromolecules as an example. The scope of the consortium, its goals and the expertise within the consortium are outlined. This article is part of the Special Issue entitled "Beyond small molecules for neurological disorders".
Neuroscience Discovery, Biology Department, AbbVie GmbH & Co KG, Knollstrasse, 67061 Ludwigshafen, Germany. Electronic address: axel.meyer@abbvie.com.
Axel H
AH
Meyer
Neuroscience Discovery, Biology Department, AbbVie GmbH & Co KG, Knollstrasse, 67061 Ludwigshafen, Germany. Electronic address: Christopher.untucht@abbvie.com.
Christopher
C
Untucht
Neuroscience Discovery, Biology Department, AbbVie GmbH & Co KG, Knollstrasse, 67061 Ludwigshafen, Germany. Electronic address: georg.terstappen@abbvie.com.
Georg C
GC
Terstappen
D000818:Animals; D035843:Biomedical Research; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000502:physiology*; D001921:Brain / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D046911:Macromolecular Substances / Q000494:pharmacology / Q000627:therapeutic use; D055818:Public-Private Sector Partnerships
D046911:Macromolecular Substances
Brain delivery; IMI-JU; Public-private partnership